• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations".

作者信息

Scheiner Bernhard, Pinter Matthias

机构信息

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Liver Cancer (HCC) Study Group Vienna, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Liver Cancer (HCC) Study Group Vienna, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

出版信息

J Hepatol. 2022 Aug;77(2):576-577. doi: 10.1016/j.jhep.2022.04.030. Epub 2022 May 5.

DOI:10.1016/j.jhep.2022.04.030
PMID:35526786
Abstract
摘要

相似文献

1
Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations".回复：“CRAFITY评分：酪氨酸激酶抑制剂与免疫疗法联合治疗肝细胞癌患者的一种有前景的预后预测指标”
J Hepatol. 2022 Aug;77(2):576-577. doi: 10.1016/j.jhep.2022.04.030. Epub 2022 May 5.
2
The CRAFITY score: A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations.CRAFITY评分：酪氨酸激酶抑制剂与免疫疗法联合治疗肝细胞癌患者的一种有前景的预后预测指标。
J Hepatol. 2022 Aug;77(2):574-576. doi: 10.1016/j.jhep.2022.03.018. Epub 2022 Mar 26.
3
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.免疫治疗肝细胞癌患者的预后——CRAFITY 评分的建立和验证。
J Hepatol. 2022 Feb;76(2):353-363. doi: 10.1016/j.jhep.2021.09.035. Epub 2021 Oct 12.
4
Reply to: "The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy".回复：“CRAFITY评分：接受免疫治疗的肝细胞癌患者预后预测的新指南”。
J Hepatol. 2022 May;76(5):1233-1234. doi: 10.1016/j.jhep.2022.02.002. Epub 2022 Feb 14.
5
Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis.CRAFITY 评分对接受免疫治疗的肝细胞癌的预后意义：系统评价和荟萃分析。
BMC Cancer. 2023 Mar 13;23(1):236. doi: 10.1186/s12885-023-10686-9.
6
The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy.CRAFITY评分：接受免疫治疗的肝细胞癌患者预后预测的新指标。
J Hepatol. 2022 May;76(5):1232-1233. doi: 10.1016/j.jhep.2021.12.033. Epub 2022 Jan 19.
7
Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?CRAFITY 评分是否能更好地预测接受局部免疫治疗的肝细胞癌患者的预后和不良事件？
Hepatol Int. 2023 Oct;17(5):1279-1288. doi: 10.1007/s12072-023-10535-8. Epub 2023 May 2.
8
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.在接受阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者中，C 反应蛋白和甲胎蛋白对免疫治疗评分的预后影响：一项多中心回顾性研究。
Hepatol Int. 2022 Oct;16(5):1150-1160. doi: 10.1007/s12072-022-10358-z. Epub 2022 Jun 24.
9
The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy.MAPS-CRAFITY 评分：一种新的预测工具，可预测不可切除的肝细胞癌接受靶向治疗联合免疫治疗的疗效。
Hepatol Int. 2023 Dec;17(6):1519-1531. doi: 10.1007/s12072-023-10580-3. Epub 2023 Sep 14.
10
The GRAPHS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with immunotherapy.GRAPHS-CRAFITY 评分：一种新型疗效预测工具，用于治疗不可切除的肝细胞癌的免疫治疗。
Radiol Med. 2024 Feb;129(2):188-201. doi: 10.1007/s11547-023-01753-z. Epub 2024 Jan 5.